Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:Japan |
| gptkbp:ATCCode |
L01EA01
|
| gptkbp:brand |
gptkb:Jakafi
gptkb:Jakavi |
| gptkbp:CASNumber |
941678-49-5
|
| gptkbp:chemicalFormula |
C17H18N6
|
| gptkbp:genericName |
gptkb:ruxolitinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jakavi
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
JAK1 inhibitor
JAK2 inhibitor |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
dizziness headache infections neutropenia thrombocytopenia |
| gptkbp:usedFor |
gptkb:myelofibrosis
gptkb:polycythemia_vera gptkb:graft-versus-host_disease |
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|